Can an ultrasound score replace MRI for fatty pancreas diagnosis?

NCT ID NCT07722689

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study tests whether a new ultrasound scoring system can accurately measure fat buildup in the pancreas. Researchers will compare ultrasound results with MRI, the current gold standard, in 36 adults with fatty pancreas. The goal is to see if ultrasound can serve as a simpler, more accessible diagnostic tool.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If validated, this ultrasound scoring system could offer a simpler, cheaper way to diagnose and grade fatty pancreas without the need for MRI.
What could go wrong
This is a small, early-stage observational study with only 36 participants. The ultrasound score may not match MRI accuracy well enough to replace it in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

36 people

The number who actually took part.

Started

Oct 2020

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will enroll adult male and female patients aged 18-65 years who are referred to the Pancreatic Diseases Unit with a hyperechoic pancreas on abdominal ultrasound.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female patients aged 18 to 65 years. * Diagnosis of fatty pancreas confirmed by magnetic resonance imaging (MRI). * Adequate pancreatic visualization on abdominal ultrasound, defined as visualization of at least 50% of the pancreatic parenchyma. * Provision of written informed consent, signed and dated prior to study enrollment. * Ability to understand the nature of the study and to comply with all study procedures and protocol requirements. Exclusion Criteria: * Age \<18 years or \>65 years. * Any psychiatric condition, cognitive impairment, or other circumstance that, in the investigator's judgment, may compromise the participant's ability to comply with the study procedures or protocol requirements. * Patients with a diagnosis of chronic pancreatitis, pancreatic neoplasms, congenital pancreatic disorders, viral infections, iron overload disorders, or a history of medication use or other medical conditions that may increase pancreatic echogenicity, thereby acting as potential confounding factors in the interpretation of the ultrasound findings.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fatty pancreas are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fondazione Policlinico Universitario Agostino Gemelli

    Roma, 00168, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.